Antheia, Ginkgo Bioworks: synthetic-biology medicines partnership
Antheia, a synthetic biology company focused on next-generation plant-inspired medicines, is partnering with Gingko Bioworks, a firm working on building a horizontal platform for cell programming, to accelerate development and production of essential medicines. Antheia reportedly plans to leverage Ginkgo's high-throughput enzyme design and screening capabilities to broaden its pipeline of critical active pharmaceutical ingredients (APIs) and key starting materials (KSMs).
“Antheia is committed to using synthetic biology to enable more equitable access to essential medicines," said Kristy Hawkins, CSO and co-founder at Antheia. "By partnering with Ginkgo Bioworks, a global leader in organism engineering, we are greatly increasing our ability to develop essential medicines at the speed and scale necessary to drive change in global pharma supply chains."